DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit
December 03 2020 - 3:30PM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in
precision dermatology enabled by a non-invasive skin genomics
platform, announced today the presentation of a precision medicine
focused session at the fourth annual Dermatology Drug Development
Summit. Held virtually this year, the Dermatology Drug Development
Summit is the only industry-focused meeting dedicated to
innovating, accelerating, and sharing pharmaceutical best practice
on the development and bringing to market of new dermatological
drugs, in the treatment of high unmet need.
The session, titled, “Stickering it to Skin Disease: The Drive
for Precision and Personalized Dermatology,” presented by Michael
D. Howell, PhD, Chief Scientific Officer of DermTech, explored the
current approaches to precision medicine in dermatology and the
integration of precision medicine and biomarker approaches in
clinical trials. Howell reviewed DermTech’s proprietary Smart
Sticker platform and its use in early detection of skin cancers
including cutaneous melanoma. Howell also discussed how
non-invasive skin sampling can enhance precision medicine by
detecting genomic and proteomic changes in the skin without the
need for a skin biopsy. Finally, Howell discussed how the expanded
use of DermTech’s breakthrough tool can guide personalized
approaches to disease diagnosis and intervention.
The presentation is available for viewing here.
“The Dermatology Drug Development Summit brings together leaders
in academia, government, and industry with a goal of driving
innovative medicine in dermatology. The DermTech Smart Sticker is
an innovative platform that non-invasively assesses genomic and
proteomic changes in the skin before those changes can be visually
detected. With more than 3,000 potentially identifiable
dermatological diseases and an ever increasing armamentarium of
therapies, the Smart Sticker technology enables innovative
approaches to precision and personalized dermatology,” commented
Howell.
About DermTech:
DermTech is the leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by our non-invasive skin genomics platform. DermTech’s mission is
to transform the practice of dermatology through more accurate
diagnosis and treatment, and the elimination of unnecessary
surgery, leading to improved patient care and lower costs. DermTech
provides genomic analysis of skin samples collected non-invasively
using an adhesive patch rather than a scalpel. DermTech markets and
develops products that facilitate the early detection of skin
cancers, and is developing products that assess inflammatory
diseases and customize drug treatments. For additional information
on DermTech, please visit DermTech’s investor relations site at:
www.DermTech.com.
Forward-looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue,” and similar
expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations with respect to: the performance, patient
benefits, cost-effectiveness, commercialization and adoption of
DermTech’s products, including the Smart Sticker platform, and the
market opportunity therefor. These forward-looking statements
involve significant risks and uncertainties that could cause the
actual results to differ materially from the expected results. Most
of these factors are outside of the control of DermTech and are
difficult to predict. Factors that may cause such differences
include, but are not limited to: (1) the outcome of any legal
proceedings that may be instituted against DermTech; (2) DermTech’s
ability to obtain additional funding to develop and market its
products; (3) the existence of favorable or unfavorable clinical
guidelines for DermTech’s tests; (4) the reimbursement of
DermTech’s tests by Medicare and private payors; (5) the ability of
patients or healthcare providers to obtain coverage of or
sufficient reimbursement for DermTech’s products; (6) DermTech’s
ability to grow, manage growth and retain its key employees; (7)
changes in applicable laws or regulations; (8) the market adoption
and demand for DermTech’s products and services together with the
possibility that DermTech may be adversely affected by other
economic, business, and/or competitive factors; and (9) other risks
and uncertainties included in (x) the “Risk Factors” section of the
most recent Quarterly Report on Form 10-Q filed by DermTech with
the Securities and Exchange Commission (the “SEC”), and (y) other
documents filed or to be filed by DermTech with the SEC. DermTech
cautions that the foregoing list of factors is not exclusive. You
should not place undue reliance upon any forward-looking
statements, which speak only as of the date made. DermTech does not
undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201203005796/en/
Sarah Dion sdion@dermtech.com (858) 450-4222
Crowe PR Sarah Gallagher sgallagher@crowepr.com 224.406.4709
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Apr 2024 to May 2024
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From May 2023 to May 2024